Dr. Ogunwobi obtained a medical degree from the University of Ibadan, Nigeria, a master's degree in biomedicine from the University of Hull, United Kingdom, a master's degree in clinical and translational science from the University of Florida, Gainesville, and a PhD in molecular biology from the University of East Anglia, Norwich, United Kingdom. He was the Founding Director of the Hunter College Center for Cancer Health Disparities Research. He is now the Barnett Rosenberg Professor of Biochemistry and Molecular Biology and Chairperson in the Department of Biochemistry and Molecular Biology at Michigan State University. In addition, he serves as Co-Director of the Center for Cancer Health Equity Research (CCHER) at Michigan State University. He is a translational cancer biologist whose work focuses on molecular mechanisms of progression of solid organ cancers with racial disparities, and on approaches to leverage non-coding RNA biology for potential clinical applications in cancer. His work has been funded by the National Institutes of Health, New York State, Carnegie Corporation of New York, and the National Science Foundation, among others. Dr. Ogunwobi was a Founding Contact Principal Investigator of the Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH) funded by U54 grants CA221704 and CA221705 from the National Cancer Institute. An author of 83 peer-reviewed journal articles and 3 book chapters, Dr. Ogunwobi has been issued 5 US patents for biotechnology inventions with potential clinical applications in cancer. He is the recipient of the 2022 Hunter College Presidential Award for Excellence in Scholarship or Creative Activity, and selected as a Jefferson Science Fellow by the National Academies of Sciences, Engineering, and Medicine. He is a Fellow of the Academy of Medicine Specialties of Nigeria and a Fellow of the African Academy of Sciences. He is Co-Founder of UTR Therapeutics, Inc (winner of the 2023 XSeed Award from Deerfield), and NucleoBio, Inc.